Table 1.
Full Samplea | IIV3 Vaccineesb | |
---|---|---|
Categorical descriptors, N (%) | ||
Study site (Oregon) | 361 (44) | 260 (45) |
Sex (Female) | 700 (86) | 502 (87) |
Race (White) | 650 (80) | 472 (82) |
Ethnicity (Hispanic) | 8 (10) | 58 (10) |
Child (age < 13) at home | 248 (30) | 159 (28) |
Physician | 52 (6) | 42 (7) |
Work in Hospital | 440 (54) | 319 (55) |
Work in Emergency Dept. | 155 (19) | 100 (17) |
Chronic medical conditionc | 151 (19) | 117 (20) |
Continuous descriptors, Median (SD) | ||
Age (years) | 47 (12) | 47 (12) |
Household size (0–7) | 2 (2) | 2 (1) |
Education (5-levels) | 16 (2) | 16 (2) |
Self-rated health status (5-levels) | 4 (1) | 4 (1) |
Body mass index (kg/m) | 28 (7) | 29 (7) |
Direct patient care per week (hours) | 34 (11) | 34 (11) |
Prior vaccinations, N (%) | ||
2006–07 IIV3 | 433 (53) | 379 (66) |
2007–08 IIV3 | 391 (48) | 342 (59) |
2008–09 IIV3 | 464 (57) | 399 (69) |
2009–10 IIV3 | 589 (72) | 503 (87) |
2009 MIV A(H1N1)pdm09 | 401 (49) | 358 (62) |
2010–11 IIV3 | 607 (74)b | 578 (100) |
Sum of Prior IIV3, Median (SD) | 3 (1) | 3 (1) |
p < .05
p < .01
p < .001.
Sample (N = 816) includes health care personnel with medical and vaccination records since July, 2006 and excludes those who received live attenuated influenza vaccine (LAIV) in 2010–11 and/or in any season since 2006–07.
The post-vaccination study sample consists of 578 of 607 who received trivalent inactivated influenza vaccine (IIV3) and also had sera collected at both preseason and post-vaccination.
Presence of a chronic medical condition was identified by a medical visit during the prior year in the electronic medical record for a medical condition associated with increased risk of influenza complications (codes available from the authors).